Sympathetic ophthalmia following vitrectomy for endophthalmitis after intravitreal bevacizumab

Robert A. Sisk; Janet L. Davis; Sander R. Dubovy; William E. Smiddy

doi:10.1080/09273940802409951

Sympathetic ophthalmia following vitrectomy for endophthalmitis after intravitreal bevacizumab

Robert A. Sisk, Janet L. Davis, Sander R. Dubovy, William E. Smiddy

Ophthalmology

Research output: Contribution to journal › Article

5 Scopus citations

Abstract

Purpose: To describe a case of sympathetic ophthalmia following vitrectomy for endophthalmitis after an intravitreal injection of bevacizumab. Design: Retrospective case report. Methods: An 84-year-old male developed sympathetic ophthalmia 4 months after vitrectomy for endophthalmitis following an intravitreal injection. The inciting blind eye was enucleated. Results: Histopathology demonstrated sympathetic ophthalmia and phacoanaphylactic endophthalmitis. Visual acuity improved from 20/200 to 20/30 in the sympathizing eye with a combination of oral prednisone and azathioprine. Conclusions: Sympathetic ophthalmia can develop following exogenous endophthalmitis but has a good visual prognosis with appropriate treatment.

Original language	English (US)
Pages (from-to)	236-238
Number of pages	3
Journal	Ocular Immunology and Inflammation
Volume	16
Issue number	5-6
DOIs	https://doi.org/10.1080/09273940802409951
State	Published - Sep 1 2008

Fingerprint

Keywords

Endophthalmitis
Intravitreal bevacizumab
Phacoanaphylactic endophthalmitis
Sympathetic ophthalmia
Vitrectomy

ASJC Scopus subject areas

Ophthalmology
Immunology and Allergy

Cite this

Sisk, R. A., Davis, J. L., Dubovy, S. R., & Smiddy, W. E. (2008). Sympathetic ophthalmia following vitrectomy for endophthalmitis after intravitreal bevacizumab. Ocular Immunology and Inflammation, 16(5-6), 236-238. https://doi.org/10.1080/09273940802409951

@article{8857e36dd0d34b9499563db9e40471ab,

title = "Sympathetic ophthalmia following vitrectomy for endophthalmitis after intravitreal bevacizumab",

abstract = "Purpose: To describe a case of sympathetic ophthalmia following vitrectomy for endophthalmitis after an intravitreal injection of bevacizumab. Design: Retrospective case report. Methods: An 84-year-old male developed sympathetic ophthalmia 4 months after vitrectomy for endophthalmitis following an intravitreal injection. The inciting blind eye was enucleated. Results: Histopathology demonstrated sympathetic ophthalmia and phacoanaphylactic endophthalmitis. Visual acuity improved from 20/200 to 20/30 in the sympathizing eye with a combination of oral prednisone and azathioprine. Conclusions: Sympathetic ophthalmia can develop following exogenous endophthalmitis but has a good visual prognosis with appropriate treatment.",

keywords = "Endophthalmitis, Intravitreal bevacizumab, Phacoanaphylactic endophthalmitis, Sympathetic ophthalmia, Vitrectomy",

author = "Sisk, {Robert A.} and Davis, {Janet L.} and Dubovy, {Sander R.} and Smiddy, {William E.}",

year = "2008",

month = sep

day = "1",

doi = "10.1080/09273940802409951",

language = "English (US)",

volume = "16",

pages = "236--238",

journal = "Ocular Immunology and Inflammation",

issn = "0927-3948",

publisher = "Informa Healthcare",

number = "5-6",

}

TY - JOUR

T1 - Sympathetic ophthalmia following vitrectomy for endophthalmitis after intravitreal bevacizumab

AU - Sisk, Robert A.

AU - Davis, Janet L.

AU - Dubovy, Sander R.

AU - Smiddy, William E.

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Purpose: To describe a case of sympathetic ophthalmia following vitrectomy for endophthalmitis after an intravitreal injection of bevacizumab. Design: Retrospective case report. Methods: An 84-year-old male developed sympathetic ophthalmia 4 months after vitrectomy for endophthalmitis following an intravitreal injection. The inciting blind eye was enucleated. Results: Histopathology demonstrated sympathetic ophthalmia and phacoanaphylactic endophthalmitis. Visual acuity improved from 20/200 to 20/30 in the sympathizing eye with a combination of oral prednisone and azathioprine. Conclusions: Sympathetic ophthalmia can develop following exogenous endophthalmitis but has a good visual prognosis with appropriate treatment.

AB - Purpose: To describe a case of sympathetic ophthalmia following vitrectomy for endophthalmitis after an intravitreal injection of bevacizumab. Design: Retrospective case report. Methods: An 84-year-old male developed sympathetic ophthalmia 4 months after vitrectomy for endophthalmitis following an intravitreal injection. The inciting blind eye was enucleated. Results: Histopathology demonstrated sympathetic ophthalmia and phacoanaphylactic endophthalmitis. Visual acuity improved from 20/200 to 20/30 in the sympathizing eye with a combination of oral prednisone and azathioprine. Conclusions: Sympathetic ophthalmia can develop following exogenous endophthalmitis but has a good visual prognosis with appropriate treatment.

KW - Endophthalmitis

KW - Intravitreal bevacizumab

KW - Phacoanaphylactic endophthalmitis

KW - Sympathetic ophthalmia

KW - Vitrectomy

UR - http://www.scopus.com/inward/record.url?scp=57449113449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57449113449&partnerID=8YFLogxK

U2 - 10.1080/09273940802409951

DO - 10.1080/09273940802409951

M3 - Article

C2 - 19065420

AN - SCOPUS:57449113449

VL - 16

SP - 236

EP - 238

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

SN - 0927-3948

IS - 5-6

ER -

Access to Document

10.1080/09273940802409951